Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in the brain, but they differ in molecular composition, route of administration, FDA...
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame the conversation, what questions to bring, and what to understand about medications like SSRIs before you book that...
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the subject of clinical investigation. It also carries real risks that...
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found that a single guided psilocybin session produced significant, lasting reductions in anxiety,...
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is FDA-cleared and available at licensed clinics across the DMV region. Washington DC has...
